---
document_datetime: 2024-12-17 18:08:21
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vizimpro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vizimpro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.2687448
conversion_datetime: 2025-12-18 10:00:34.266803
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Vizimpro

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                           |
|----------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------|
| IAIN/0012            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 11/12/2024                          |                                             | Annex II and PL                  |                                                                                                                   |
| R/0011               | Renewal of the marketing authorisation.                                                                                    | 12/10/2023                          | 07/12/2023                                  | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     | Vizimpro in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10757 /202209 | Periodic Safety Update EU Single assessment - dacomitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14/04/2023 | n/a | PRAC Recommendation - maintenance                                                                                                                      |
| IA/0010/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 27/02/2023 | n/a |                                                                                                                                                        |
| PSUSA/10757 /202109 | Periodic Safety Update EU Single assessment - dacomitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/05/2022 | n/a | PRAC Recommendation - maintenance                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| PSUSA/10757 /202103   | Periodic Safety Update EU Single assessment - dacomitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28/10/2021   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0007               | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 02/07/2021   | 29/06/2022 | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10757 /202009   | Periodic Safety Update EU Single assessment - dacomitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 06/05/2021   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0003/G             | This was an application for a group of variations. Update of sections 4.2 and 5.2 of the SmPC in order to revise the dosing recommendation for patients with hepatic impairment and include relevant pharmacokinetics data based on results of Study A7471058, evaluating the effect of severe hepatic impairment on the plasma PK, safety and tolerability after a single dose of dacomitinib. As a consequence, the MAH is proposing to remove the missing information 'Safety in Patient with Severe Hepatic Impairment' from the list of safety concerns in the RMP v2.0. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of | 10/12/2020   | 22/01/2021 | SmPC, Labelling and PL | Based on results of study A7471058, a dedicated hepatic impairment trial, following a single oral dose of 30 mg Vizimpro, dacomitinib exposure was unchanged for AUCinf and increased by 31% for Cmax in subjects with severe hepatic impairment (Child-Pugh class C; N=8), when compared to subjects with normal hepatic function (N=8). As a consequence, the starting dose of Vizimpro should be adjusted to 30 mg once daily in patients with severe (Child- Pugh class C) hepatic impairment. The dose may be increased to 45 mg once daily based on individual safety and tolerability after at least 4 weeks of treatment. |

<div style=\"page-break-after: always\"></div>

|                     | change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |    |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| N/0004              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                 | 27/11/2020 | 22/01/2021 | PL |                                   |
| PSUSA/10757 /202003 | Periodic Safety Update EU Single assessment - dacomitinib                                                                                        | 29/10/2020 | n/a        |    | PRAC Recommendation - maintenance |
| PSUSA/10757 /201909 | Periodic Safety Update EU Single assessment - dacomitinib                                                                                        | 17/04/2020 | n/a        |    | PRAC Recommendation - maintenance |